Excellent
Patient Risk:
Low
Summary
The provided AI content accurately reflects the Eliquis label warnings that premature discontinuation increases thrombotic risk and that spinal/epidural anesthesia or puncture can cause spinal/epidural hematoma with potential long-term or permanent paralysis. Within the limited evaluation scope (A and B), it does not contradict or materially omit the core warning concepts.
Category Scores
Accurate Statements
Premature discontinuation of ELIQUIS increases thrombotic risk.
Supported by Warnings and Precautions (5.1): premature discontinuation of any oral anticoagulant including ELIQUIS (without adequate alternative anticoagulation) increases risk of thrombotic events.
Spinal/epidural hematoma can occur with neuraxial anesthesia or spinal/epidural puncture and may result in long-term or permanent paralysis.
Supported by Warnings and Precautions (5.3) and Medication Guide counseling: epidural/spinal hematoma risk with neuraxial anesthesia or puncture; potential for long-term or permanent paralysis.
Unsupported Statements
Contradictions
Important Omissions
Specific operational/timing details from Warnings and Precautions (5.3) (e.g., do not remove indwelling epidural catheters earlier than 24 hours after last dose; next dose not earlier than 5 hours after removal; delay 48 hours after traumatic puncture) and the associated monitoring/urgent evaluation guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The core safety warnings are consistent with the label. However, the AI text (as provided) does not include the label’s specific timing/operational instructions around neuraxial catheter management and traumatic puncture, which could reduce practical safety effectiveness if relied upon for administration timing.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Primary Issue
Missing label-specific neuraxial timing and monitoring operational details from Warnings and Precautions (5.3).
Suggested Improvement
When describing the spinal/epidural hematoma warning, include the label’s key administration timing constraints for catheter removal and next dosing (and the 48-hour delay after traumatic puncture if applicable), plus the instruction to monitor for neurologic impairment and seek urgent diagnosis/treatment if compromise occurs.